CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

Core Insights - Inspira Technologies is scaling up production capabilities for its FDA-cleared INSPIRA™ ART100 system in response to anticipated demand from a European governmental authority, with advanced-stage procurement negotiations underway [1][2][3] - The ART100 system is already in clinical use in the U.S. and is recognized as a reliable device for critical care and emergency preparedness [2][3] - The company aims to fast-track revenue generation from the ART100 system while continuing to develop next-generation platforms, including the ART500 and HYLA™ blood sensor [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with the ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The ART500 is a next-generation system designed to provide oxygenation while patients remain awake and spontaneously breathing, and the HYLA™ platform offers continuous, non-invasive blood monitoring [5] - The company is positioned as an attractive platform within the critical care and MedTech landscape, reflecting broader industry trends such as consolidation and cross-sector collaboration [5]